TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient report explains four leading theories for why Alzheimer’s disease damages brain cells: amyloid buildup, tau tangles, inflammation and vascular or metabolic factors. Research supports parts of these explanations, but scientists have not established one cause that accounts for every case.
A Being Patient report outlines four leading theories about what causes Alzheimer’s disease, a progressive brain disorder marked by neuron damage and loss. The theories focus on amyloid plaques, tau tangles, inflammation and vascular or metabolic problems; scientists have not established one explanation that accounts for every case.
The best-known account is the amyloid hypothesis. Beta-amyloid fragments can accumulate in spaces between neurons and form plaques. Researchers have proposed that this buildup may disrupt cell communication and trigger further damage, including changes to tau. Amyloid can begin accumulating years before symptoms, but that timing does not by itself prove it is the initiating cause of the disease.
A second theory focuses on tau**, a protein that normally helps stabilize structures inside neurons. In Alzheimer’s, tau can become abnormal and form tangles inside cells. These changes are associated with damaged neurons and may spread through the brain as the disease progresses. The source describes amyloid and tau as related lines of investigation, not a settled sequence that fully explains disease onset.
The report also discusses inflammation and immune activity, as well as vascular and metabolic factors, as possible contributors. Immune cells in the brain may respond to damage or protein buildup, but prolonged inflammation could also harm neurons. Problems involving blood vessels, circulation or the brain’s energy use may affect cell health. These processes may interact with amyloid and tau rather than operate as separate, exclusive explanations.
How Theories Shape Treatment Research
The competing explanations matter because they guide drug development and diagnosis. Anti-amyloid medicines Leqembi (lecanemab) and Kisunla (donanemab) are FDA-approved for people in early stages of Alzheimer’s, according to the source. Clinical trials found that they modestly slowed cognitive decline; they do not cure the disease and can carry risks, including brain swelling and bleeding, that require monitoring.
The record also shows why biological markers and clinical outcomes are not interchangeable. The source reports that Aduhelm (aducanumab) cleared amyloid plaques, but evidence of clinical benefit was unconvincing; its maker discontinued the drug in 2024. Measuring a change in a suspected disease marker does not automatically establish a meaningful improvement for patients. Better understanding of what drives neuron loss could help researchers identify which people may benefit from which treatments, and when.
Popular right now
Vitamix 5200 Professional-Grade Blender, 64 oz. Container, Black
TCL QM64L 85-Inch QD-Mini LED 4K Smart Fire TV
Vitamix Propel Series 750 Professional-Grade Blender, 4 Programs, Black
As an affiliate, we earn on qualifying purchases.
From Plaques to Multiple Mechanisms
In 1906, psychiatrist Alois Alzheimer described plaques and twisted fibers in the brain of Auguste Deter, a patient who had died at 55 after years of worsening memory loss and confusion. Those findings are now associated with amyloid plaques and tau tangles. They remain defining features of Alzheimer’s, but identifying them has not answered what starts the disease or why its course varies.
Alzheimer’s damages neurons and the connections between them. Early effects often involve the hippocampus, which helps form new memories; later damage can affect language, judgment, behavior and coordination. The source cites the Alzheimer’s Association’s 2026 facts-and-figures report, estimating 7.4 million Americans age 65 and older are living with Alzheimer’s dementia.
Amyloid also plays a growing role in testing. The report says plaques can be identified through amyloid PET scans and spinal-fluid testing, and that the FDA cleared the first blood test to aid in identifying amyloid pathology linked to Alzheimer’s in May 2025. Such tests provide evidence about pathology; they do not, on their own, resolve the broader question of what causes the disease.
“Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.”
— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, as quoted by Being Patient
What Starts Neuron Damage?
The central uncertainty is whether amyloid buildup initiates Alzheimer’s, contributes to damage after another process has begun, or plays different roles at different stages. The source notes that some researchers have suggested beta-amyloid could have protective functions, while evidence from drugs that block its production has raised concerns. Those arguments do not settle the question; they show that the protein’s role may be more complicated than a single harmful mechanism.
It is also unclear how amyloid, tau, immune activity and vascular or metabolic changes interact, or why people with similar markers can have different symptoms and rates of decline. The supplied report gives no evidence that one of the four theories alone explains all cases. Researchers continue to investigate how these processes relate to inherited risk, aging and other factors.
Research Beyond Amyloid Alone
Research will continue testing treatments that target amyloid and tau, alongside approaches aimed at inflammation and other contributors. Investigators will need to measure both changes in biological markers and outcomes that matter to patients, such as memory and daily functioning. The approved anti-amyloid drugs also require continued monitoring for side effects, as described in the source.
For readers, the current picture is not a single confirmed cause but several plausible, overlapping mechanisms under study. The report does not identify a forthcoming milestone that would settle the debate. Further trials and research into disease biology will help clarify which pathways drive damage, when they do so, and whether targeting them can slow decline.
Key Questions
What causes Alzheimer’s disease?
No single cause is established. Researchers are studying amyloid buildup, tau changes, inflammation and vascular or metabolic factors, which may interact.
Are amyloid plaques the confirmed cause?
Amyloid plaques are a defining feature and a major treatment target, but their presence does not prove they are the sole cause. Scientists continue to debate how amyloid relates to other brain changes.
What is the difference between amyloid and tau?
Amyloid plaques collect in spaces between neurons. Tau tangles form inside neurons after changes to a protein that normally helps support cell structures.
Do anti-amyloid drugs cure Alzheimer’s?
No. The source says Leqembi and Kisunla modestly slowed cognitive decline in clinical trials among people in early stages; they are not cures and require monitoring for risks.
Can an amyloid test determine what caused a person’s symptoms?
Amyloid PET, spinal-fluid testing and the blood test described in the report can help identify amyloid pathology. A result does not, by itself, establish the full cause of symptoms or explain how the disease will progress.
Source: rss
